Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Clinical trial NCT01004731 · COMPLETED

Trial details

NCT number: NCT01004731
Sponsor: University of Alabama at Birmingham
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stage IV Non-Small Cell Lung Cancer

Start date: 2001-06-01
Primary completion: 2002-01-01
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.